Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PCI Biotech Holding ASA completes first group in the intra-tumour light dose escalation part of the ENHANCE study-Reuters


Friday, 24 Jan 2014 02:39am EST 

PCI Biotech Holding ASA:Says the treatment evaluation of the first group in the intra-tumour light dose escalation part of the ENHANCE study has been completed-Reuters.Says ENHANCE is a phase II study of Amphinex in combination with the cytotoxic agent bleomycin in recurrent head and neck cancer patients.Says no safety concerns were raised and a clear but insufficient tumour response was seen at this light dose level.Says a Dose Review Committee (DRC) of clinical experts and company representatives has been established to evaluate the results and provide recommendation for the continuation of the study.Says the DRC has recommended that the light dose is escalated according to the protocol.Says patients for the next light dose level are currently being screened and will be treated with Amphinex as soon as possible. 

Company Quote

11.8
0.8 +7.27%
19 Dec 2014